Research
-
PNAS: Decoding the Mystery of American Pain Reveals a Warning for the Future
In America today, the elderly report less pain than those in midlife. This is the mystery of American pain.
Categorized in -
AJMC: Policies to Address Surprise Billing Can Affect Health Insurance Premiums
Policies to address surprise billing could reduce health insurance premiums by 1% to 5%.
-
Know Your Epidemic, Know Your Response: Early Perceptions of COVID-19 and Self-Reported Social Distancing in the United States
we study individual’s perceptions on COVID-19 and social distancing during the week of March 10–16, 2020, a week when COVID-19 was officially declared to be a pandemic by WHO and when new infections in the US were more than doubling every three days.
Categorized in -
Georgia’s Latest 1332 Proposal Continues To Violate the ACA
Scholars from the USC-Brookings Schaeffer Initiative for Health Policy Georgia’s latest 1332 Proposal, analyzing its major analytical errors and procedural deficiencies that render it unapprovable.
-
Impacts on the U.S. Macroeconomy of Mandatory Business Closures in Response to the COVID-19 Pandemic
A mandatory business closure over three months results in a 20.3% decline of U.S. GDP on an annual basis, or $4.3 trillion, and an employment decline of 22.4%, representing 35.3 million workers.
Categorized in -
Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review
This analysis highlights that most cost-utility analyses that cite high cost-effectiveness thresholds also result in greater incremental cost-effectiveness ratios for the novel interventions that they investigate.
Categorized in -
Blood‐Based Biomarkers for Alzheimer’s Pathology and the Diagnostic Process for a Disease‐Modifying Treatment: Projecting the Impact on the Cost and Wait Times
Blood‐based biomarker tests are a promising tool to improve triaging Alzheimer’s disease at the primary care level.
Categorized in -
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Categorized in -
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Categorized in -
The “Advancing American Kidney Health” Executive Order: Challenges and Opportunities for the Large Dialysis Organizations
This perspective in the American Journal of Kidney Diseases examines how the “Advancing American Kidney Health” Executive Order (AAKH) might reshape the US dialysis market.
Categorized in